論文

査読有り
2017年10月

Surgery With or Without Postoperative Radiation Therapy for Early-stage External Auditory Canal Squamous Cell Carcinoma: A Meta-analysis

OTOLOGY & NEUROTOLOGY
  • Ryohei Oya
  • ,
  • Yukinori Takenaka
  • ,
  • Kazuya Takemura
  • ,
  • Naoki Ashida
  • ,
  • Kotaro Shimizu
  • ,
  • Takahiro Kitamura
  • ,
  • Yoshifumi Yamamoto
  • ,
  • Atsuhiko Uno

38
9
開始ページ
1333
終了ページ
1338
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1097/MAO.0000000000001533
出版者・発行元
LIPPINCOTT WILLIAMS & WILKINS

Objective: External auditory canal squamous cell carcinoma (EACSCC) is a rare disease with no standard treatment supported by high-level evidence. The aim of this study was to investigate EACSCC prognoses according to treatment modality and thus determine the optimal intervention for early-stage disease.
Data Sources: PubMed, Scopus, and Ichushi-Web searches of the English and Japanese-language literature published between January 1, 2006 and December 31, 2016 were performed using the key words "external auditory canal cancer'' and "temporal bone cancer.''
Study Selection: Articles related to EACSCC that include the 5-year overall survival rate or individual patient data for histological types, follow-up periods, and final outcomes were enrolled.
Data Extraction: Sex, age, Moody's modified Pittsburgh stage, type of treatment modality, type of operation, followup period, and 5-year survival rates were extracted.
Data Synthesis: Twenty articles were used for the aggregate meta-analysis using a random-effects model, and 18 articles that reported 99 patients with early-stage EACSCC were used for the individual patient data meta-analysis.
Conclusion: The 5-year overall survival rate of early-stage EACSCC was 77%. Postoperative radiation therapy (PORT) was performed in 45% of stage I patients and 68% of stage II patients. Survival analysis of all patients showed no differences between the surgery-only and PORT groups; however, PORT exhibited a better prognosis than surgery alone among patients with stage I disease (p = 0.003, log-rank test). This result indicated that PORT can be the standard therapy for stages I and II EACSCC.

リンク情報
DOI
https://doi.org/10.1097/MAO.0000000000001533
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/28796084
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000418475600030&DestApp=WOS_CPL
ID情報
  • DOI : 10.1097/MAO.0000000000001533
  • ISSN : 1531-7129
  • eISSN : 1537-4505
  • PubMed ID : 28796084
  • Web of Science ID : WOS:000418475600030

エクスポート
BibTeX RIS